Project Grant R21AI188227
Award Date
7/25/25
Completion Date
6/30/27
Dollars Obligated
$474K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...
This Project Grant award of $455,000 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to decrease sepsis mortality in the pediatric population. The key products and services to be delivered include: Developing an AI-guided early sepsis identification tool to enable timely diagnosis and treatment. Performing sepsis phenotyping and creating digital twin patient models to predict personalized treatment responses....
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $418,750.00 to The Feinstein Institutes for Medical Research to conduct research on T cell receptor-mediated T cell activation in neonatal and pediatric sepsis. The goal is to gain insight into how T cell memory influences sepsis-associated organ dysfunction, by comparing responses between human neonates with sepsis and...
This $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the clinical validation of Prenosis, Inc.'s IMMUNIX platform, a precision medicine endotyping solution for sepsis. The project aims to: 1) validate the IMMUNOSCAN multiplex rapid test and mapping functions to Luminex immunoassays; 2) validate a parsimonious model for point-of-care endotyping; and 3) demonstrate the ability to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $721,728 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the Regents of the University of Michigan. The grant aims to investigate how persistent viral infections, such as human cytomegalovirus and Epstein-Barr virus, may worsen clinical outcomes and decrease response to immunomodulatory therapies in pediatric patients with sepsis. The research project will leverage...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...
The University of Rochester was awarded a $462,000 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate how the microbiome in healthy human blood differentially "primes" or trains neutrophils, leading to varied inflammatory responses during sepsis. The research aims to elucidate the mechanisms underlying this microbiome-mediated immune...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to unravel the relationships between gut and blood microbial signatures and immune responses in sepsis patients. The $403,750 award to Duke University will support a prospective longitudinal study to integrate gut microbial community profiling, metabolomics, measures of intestinal permeability, and blood microbial signatures with immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish a CRISPR-based airway organoid platform for screening mechanisms involved in airway epithelial cell and intraepithelial airway macrophage interactions. The goal is to identify novel mediators of airway immune cell homeostasis,...
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) in the amount of $409,347 provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), from September 1, 2024 to July 31, 2026. The project aims to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and resulting pneumonia and sepsis, as well as...